EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Combating Drug‐Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics

Silvi Gautam, Jahanvi Saini, Shabaaz Begum Jameel Pasha iD, Divakar Sharma iD, Divya Venugopal

Pulmonary Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/pm/3346306 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pulmonary Medicine, online erschienen am 17.08.2026. Verfasst von Silvi Gautam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Mycobacterium tuberculosis. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasing prevalence of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) Mycobacterium tuberculosis has emerged as a major global health concern. Advanced molecular diagnostics, including rapid assays, have improved resistance detection; however, resource‐limited settings remain underserved. Nanotechnology‐based drug delivery systems, including polymeric carriers, solid lipid nanoparticles, and silver nanoparticles, can provide targeted delivery, prolonged release, and improved bioavailability. Drug repurposing strategies using existing drugs like linezolid, celecoxib, and nitazoxanide also show a promising option in combating drug‐resistant TB while reducing treatment duration. Host‐directed therapies (HDTs) and natural products offer complementary strategies by enhancing host immune responses and providing multitarget antimycobacterial effects. This review emphasizes the drug resistance mechanisms and advancements in novel theranostics. Despite significant progress, challenges related to cost‐effective scalability, accessibility of advanced diagnostics, and optimization of therapeutic systems continue to limit clinical translation. Future research must prioritize multidisciplinary collaborations to accelerate drug development, enhance diagnostic capabilities, and expand nanotechnology‐based solutions to address the TB epidemic effectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsTuberculosis, Multidrug-ResistantMycobacterium tuberculosisHumansDrug Delivery SystemsDrug RepositioningHost-Directed TherapyNanotechnology

Stichwörter der Autor:innen

Mycobacterium tuberculosisantibioticsdrug repurposingdrug resistancemutationnanotechnology

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Department of Microbiology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in.
  • Department of Biotechnology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in.

ORCID-Profile: Shabaaz Begum Jameel Pasha, Divakar Sharma

Zitieren

APA

Gautam, S., Saini, J., Pasha, S. B. J., Sharma, D., & Venugopal, D. (2026). Combating Drug‐Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics. Pulmonary Medicine, 2026(1). https://doi.org/10.1155/pm/3346306

Vancouver

Gautam S, Saini J, Pasha SBJ, Sharma D, Venugopal D. Combating Drug‐Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics. Pulmonary Medicine. 2026;2026(1). doi:10.1155/pm/3346306

BibTeX
@article{Gautam2026,
  author = {Gautam, Silvi and Saini, Jahanvi and Pasha, Shabaaz Begum Jameel and Sharma, Divakar and Venugopal, Divya},
  title = {Combating Drug‐Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics},
  journal = {Pulmonary Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/pm/3346306}
}
Kostenlos starten →